Lymphoma

淋巴瘤和霍奇金病项目的目标是更好地了解 淋巴肿瘤的生物学基础，并应用这些知识，以提高诊断和 治疗这些疾病。为了实现这一目标，我们有一个广泛的研究计划， 淋巴瘤发病机制，临床病理关系，新的治疗方法和 临床试验我们的资源包括一个大型的临床数据库，其中包括> 10，000例淋巴瘤和5，000例霍奇金淋巴瘤。 淋巴瘤的随访期为40年，组织库包含5，500个新鲜冷冻的 标本我们计划中的27名成员代表了学校的11个部门。 医学和工程学院。淋巴瘤和霍奇金病项目的研究人员 有16个赠款，包括1个P01; 1个SCOR; 1个P20; 4个R 01; 1个T32; 3个K和其他同行评审的奖项。的 2008年，国家癌症研究所的年度直接支助总额为350万美元。我们的计划强调翻译 从临床到诊断和新疗法的研究，从临床到实验室， 组织研究与临床事件的相关性。在过去的五年里， 出版物已出现在同行评审的期刊上。以实验室为基础的项目侧重于 检测单个细胞中的信号通路;淋巴瘤发生，关注MYC 癌基因和丙型肝炎的免疫反应;开发新的诊断方法， 基因发现和针对这些基因的新的单克隆抗体; 治疗性疫苗接种的新方法。我们的临床研究重点是免疫治疗和新型 我们小组的综合模式治疗和概念已经进入了有影响力的第三阶段 东部肿瘤协作组（ECOG）的临床试验。

The goal of the Lymphoma and Hodgkin Disease Program is to gain a better understanding of the biology underlying lymphoid neoplasms and to apply this knowledge to improve the diagnosis and treatment of these disorders. In working toward this goal, we have a broad research program with major themes of lymphoma pathogenesis, clinical pathological relationships, novel therapeutics and clinical trials. Our resources include a large clinical database of >10,000 lymphoma and 5,000 Hodgkin lymphoma over a follow-up period of 40 years and a tissue bank containing 5,500 fresh-frozen specimens. The 27 members within our program represent 11 departments within the School of Medicine and the School of Engineering. Investigators in the Lymphoma and Hodgkin Disease Program have 16 grants, including 1 P01; 1 SCOR; 1 P20; 4 R01; 1 T32; 3 K and other peer-reviewed awards. The annual direct NCI support in 2008 totaled $3.5 million. Our program has emphasized translational research to the clinic in diagnostics and novel therapeutics and from the clinic to the laboratory in the correlation of studies on tissues matched with clinical events. During the past five years, over 300 publications have appeared in peer-reviewed journals. Laboratory-based projects are focused on the detection of signaling pathways in individual cells; lymphomagenesis, with attention to the MYC oncogene and the immune response to hepatitis C; development of novel diagnostics, including new gene discovery and new monoclonal antibodies directed against these genes; and model systems for a new method of therapeutic vaccination. Our clinical studies have a focus on immunotherapy and novel combined modality treatments and concepts from our group have moved into influential Phase III clinical trials in the Eastern Cooperative Oncology Group (ECOG).